A recent study has used α-GalCer as an adjuvant with DNA vaccination against HPV-16 oncoprotein E7 to generate high numbers of E7-specific CD8+ T-cells protective against the transplantable TC-1 (HPV-16+) tumour model in mice [39]. Here, CD8A is linked to neoplasm.